Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker GIS
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | Jacqueline Williams-Roll Chief Human Resources Officer | GIS General Mills, Inc. | Sale | 10,000 | $33.97 | $339.7K Sale | Form 4 ↗ |
| May 12, 2026 | Jacqueline Williams-Roll Chief Human Resources Officer | GIS General Mills, Inc. | Sale | 10,000 | $34.27 | $342.7K Sale | Form 4 ↗ |
| May 12, 2026 | Ricardo Fernandez Segment President | GIS General Mills, Inc. | Sale | 7,995 | $34.50 | $275.8K Sale | Form 4 ↗ |
| Dec 19, 2025 | Paul Joseph Gallagher Chief Supply Chain Officer | GIS General Mills, Inc. | Sale | 1,500 | $48.15 | $72.2K Sale | Form 4 ↗ |
| Sep 19, 2025 | Jacqueline Williams-Roll Chief Human Resources Officer | GIS General Mills, Inc. | Sale | 4,000 | $50.04 | $200.2K Sale | Form 4 ↗ |
| May 15, 2025 | Pankaj MN Sharma Segment President | GIS General Mills, Inc. | Sale | 3,643 | $54.12 | $197.2K Sale | Form 4 ↗ |
| Mar 7, 2025 | Jeffrey L. Harmening Chairman of the Board & CEO, Director | GIS General Mills, Inc. | Sale | 11,379 | $65.00 | $739.6K Sale | Form 4 ↗ |
| Dec 20, 2024 | Paul Joseph Gallagher Chief Supply Chain Officer | GIS General Mills, Inc. | Sale | 1,041 | $64.50 | $67.1K Sale | Form 4 ↗ |
| Nov 15, 2024 | Maria Sastre Director | GIS General Mills, Inc. | Sale | 1,000 | $63.66 | $63.7K Sale | Form 4 ↗ |
| Oct 23, 2024 | Jeffrey L. Harmening Chairman of the Board & CEO, Director | GIS General Mills, Inc. | Sale | 46,500 | $68.61 | $3.2M Sale | Form 4 ↗ |
| Oct 15, 2024 | Mark A. Pallot Chief Accounting Officer | GIS General Mills, Inc. | Sale | 2,251 | $71.25 | $160.4K Sale | Form 4 ↗ |
| Oct 15, 2024 | Mark A. Pallot Chief Accounting Officer | GIS General Mills, Inc. | Sale | 1,007 | $71.28 | $71.8K Sale | Form 4 ↗ |
| Oct 15, 2024 | Mark A. Pallot Chief Accounting Officer | GIS General Mills, Inc. | Sale | 4,825 | $71.29 | $344.0K Sale | Form 4 ↗ |
| Sep 27, 2024 | Jonathon Nudi Group President | GIS General Mills, Inc. | Sale | 9,647 | $74.39 | $717.6K Sale | Form 4 ↗ |
14 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:00 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances